Global Rheumatology Therapeutics Market valued approximately USD 44.38 billion in 2018 is anticipated to grow with a healthy growth rate of more than 2.73% over the forecast period 2019-2026. The Rheumatology Therapeutics Market is continuously growing in the global scenario at significant pace. Rheumatology therapeutics market consists of therapeutics used for the treatment of rheumatic disorders, which include rheumatoid arthritis, juvenile rheumatoid arthritis, spondylarthritis, systemic lupus erythematosus, and systemic sclerosis. It is also associated with pain disorders in joints, ligaments and muscles. Rising incidence of rheumatology diseases, rising geriatric population worldwide are the substantial driving factors of the market during the forecast period. Additionally, increasing awareness regarding diseases remittances therapies and growing healthcare expenditure are another factor that impelling the demand of rheumatology therapeutics across the globe. Moreover, technological advancements in pharmaceutical field and increasing investments in healthcare industry for research and development activities are the factors that likely to create numerous opportunity in the near future. However, high capital investment in drug development and presence of alternative such as biosimilar are the factors that limiting the growth of the market during the forecast period.

The regional analysis of Global Rheumatology Therapeutics Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share due to rising geriatric population, growing healthcare expenditure and high adoption of biopharmaceuticals for the treatment in the region. Europe is estimated to grow at significant growth rate in the global Rheumatology Therapeutics market over the upcoming years. Further, Asia-Pacific is anticipated to exhibit higher growth rate / CAGR over the forecast period 2019-2026 due to increasing prevalence of rheumatology diseases and rising number of patient population across the region.

The major market player included in this report are:
AbbVie
Pfizer
Bristol-Myers Squibb Company
Merck & Co.
Amgen
Janssen Biotech
Novartis AG
Genentech
Takeda Pharmaceutical
Sanofi

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Disease Type:
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Osteoarthritis
- Lupus
- Gout
- Others

By Drug Type:
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Analgesics
- Disease Modifying Anti-Rheumatic Drugs (DMARDs)
- Corticosteroids
- Others

By Distribution Channel:
- Retail Pharmacy
- Online Pharmacy
- Hospitals
- Others

By Regions:
- North America
- U.S.
- Canada
Furthermore, years considered for the study are as follows:
Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026

Chapter 1. Executive Summary

1. 1. Market Snapshot
1. 2. Key Trends
   1. 3.1. Rheumatology Therapeutics Market, by Disease Type, 2016-2026 (USD Billion)
   1. 3.2. Rheumatology Therapeutics Market, by Drug Type, 2016-2026 (USD Billion)
   1. 3.3. Rheumatology Therapeutics Market, by Distribution Channel, 2016-2026 (USD Billion)
   1. 3.4. Rheumatology Therapeutics Market, by Region, 2016-2026 (USD Billion)
1. 4. Estimation Methodology
1. 5. Research Assumption

Chapter 2. Rheumatology Therapeutics Market Definition and Scope

2. 1. Objective of the Study
2. 2. Market Definition & Scope
   2. 2.1. Industry Evolution
   2. 2.2. Scope of the Study
2. 3. Years Considered for the Study
2. 4. Currency Conversion Rates

Chapter 3. Rheumatology Therapeutics Market Dynamics

3. 1. See Saw Analysis
   3. 1.1. Market Drivers
   3. 1.2. Market Challenges
   3. 1.3. Market Opportunities

Chapter 4. Rheumatology Therapeutics Market Industry Analysis

4. 1. Porter’s 5 Force Model
   4. 1.1. Bargaining Power of Buyers
   4. 1.2. Bargaining Power of Suppliers
   4. 1.3. Threat of New Entrants
   4. 1.4. Threat of Substitutes
   4. 1.5. Competitive Rivalry
   4. 1.6. Futuristic Approach to Porter’s 5 Force Model
4. 2. PEST Analysis
   4. 2.1. Political Scenario
   4. 2.2. Economic Scenario
   4. 2.3. Social Scenario
   4. 2.4. Technological Scenario
4. 3. Key Buying Criteria (On Demand)
4. 4. Regulatory Framework (On Demand)
4. 5. Investment Vs Adoption Scenario (On Demand)
4. 6. Analyst Recommendation & Conclusion

Chapter 5. Rheumatology Therapeutics Market, by Disease Type

5. 1. Market Snapshot
5. 2. Market Performance - Potential Model
5. 3. Key Market Players
5. 4. Rheumatology Therapeutics Market, Sub Segment Analysis
   5. 4.1. Rheumatoid Arthritis
      5. 4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      5. 4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
   5. 4.2. Ankylosing Spondylitis
      5. 4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      5. 4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
   5. 4.3. Osteoarthritis
      5. 4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      5. 4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
   5. 4.4. Lupus
      5. 4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      5. 4.4.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
   5. 4.5. Gout
## 5.4.5. Market estimates & forecasts, 2016-2026 (USD Billion)

### 5.4.5.1. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

### 5.4.5.2. Others

- 5.4.6.1. Market estimates & forecasts, 2016-2026 (USD Billion)
- 5.4.6.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

### Chapter 6. Rheumatology Therapeutics Market, by Drug Type

#### 6.1. Market Snapshot

#### 6.2. Market Performance - Potential Model

#### 6.3. Key Market Players

#### 6.4. Rheumatology Therapeutics Market, Sub Segment Analysis

- 6.4.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  - 6.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
  - 6.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 6.4.2. Analgesics
  - 6.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
  - 6.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 6.4.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
  - 6.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
  - 6.4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 6.4.4. Corticosteroids
  - 6.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
  - 6.4.4.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 6.4.5. Others
  - 6.4.5.1. Market estimates & forecasts, 2016-2026 (USD Billion)
  - 6.4.5.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

### Chapter 7. Rheumatology Therapeutics Market, by Distribution Channel

#### 7.1. Market Snapshot

#### 7.2. Market Performance - Potential Model

#### 7.3. Key Market Players

#### 7.4. Rheumatology Therapeutics Market, Sub Segment Analysis

- 7.4.1. Retail Pharmacy
  - 7.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
  - 7.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 7.4.2. Online Pharmacy
  - 7.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
  - 7.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 7.4.3. Hospitals
  - 7.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
  - 7.4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 7.4.4. Others
  - 7.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
  - 7.4.4.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

### Chapter 8. Rheumatology Therapeutics Market, by Regional Analysis

#### 8.1. Rheumatology Therapeutics Market, Regional Market Snapshot (2016-2026)

#### 8.2. North America Rheumatology Therapeutics Market Snapshot

- 8.2.1. U.S.
  - 8.2.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
  - 8.2.1.2. Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.2.1.3. Drug Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.2.1.4. Distribution Channels breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.2.2. Canada
  - 8.2.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
  - 8.2.2.2. Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.2.2.3. Drug Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.2.2.4. Distribution Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)

#### 8.3. Europe Rheumatology Therapeutics Market Snapshot

- 8.3.1. U.K.
  - 8.3.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
  - 8.3.1.2. Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.3.1.3. Drug Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.3.1.4. Distribution Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.3.2. Germany
  - 8.3.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
  - 8.3.2.2. Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.3.2.3. Drug Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.3.2.4. Distribution Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.3.3. Rest of Europe
  - 8.3.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
  - 8.3.3.2. Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.3.3.3. Drug Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
  - 8.3.3.4. Distribution Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4. Asia Rheumatology Therapeutics Market Snapshot

8.4.1. China
- 8.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
- 8.4.1.2. Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.4.1.3. Drug Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.4.1.4. Distribution Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)

8.4.2. India
- 8.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
- 8.4.2.2. Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.4.2.3. Drug Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.4.2.4. Distribution Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)

8.4.3. Japan
- 8.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
- 8.4.3.2. Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.4.3.3. Drug Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.4.3.4. Distribution Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)

8.4.4. Rest of Asia Pacific
- 8.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
- 8.4.4.2. Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.4.4.3. Drug Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.4.4.4. Distribution Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)

8.5. Latin America Rheumatology Therapeutics Market Snapshot

8.5.1. Brazil
- 8.5.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
- 8.5.1.2. Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.5.1.3. Drug Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.5.1.4. Distribution Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)

8.5.2. Mexico
- 8.5.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
- 8.5.2.2. Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.5.2.3. Drug Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.5.2.4. Distribution Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)

8.6. Rest of The World

8.6.1. South America
- 8.6.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
- 8.6.1.2. Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.6.1.3. Drug Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.6.1.4. Distribution Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)

8.6.2. Middle East and Africa
- 8.6.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
- 8.6.2.2. Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.6.2.3. Drug Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
- 8.6.2.4. Distribution Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)

Chapter 9. Competitive Intelligence

9.1. Company Market Share (Subject to Data Availability)
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. AbbVie
  - 9.3.1.1. Overview
  - 9.3.1.2. Financial (Subject to Data Availability)
  - 9.3.1.3. Summary
  - 9.3.1.4. Recent Developments
- 9.3.2. Pfizer
- 9.3.3. Bristol-Myers Squibb Company
- 9.3.4. Merck & Co.
- 9.3.5. Agen
- 9.3.6. Janssen Biotech
- 9.3.7. Novartis AG
- 9.3.8. Genentech
- 9.3.9. Takeda Pharmaceutical
- 9.3.10. Sanofi

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing